30 Ağustos 2021 Dergi makalesi Açık Erişim

Mehmet; Gökhan; Pamir

Dublin Core

<?xml version='1.0' encoding='utf-8'?>
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Mehmet</dc:creator>
  <dc:creator>Gökhan</dc:creator>
  <dc:creator>Pamir</dc:creator>
  <dc:date>2021-08-30</dc:date>
  <dc:description>COVID-19 is a viral infection caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that killed a large number of patients around the world. A hyperinflammatory state resulting in a cytokine storm and adult respiratory distress syndrome seems to be the major cause of the death. Many mechanisms have been suggested in the pathogenesis of COVID-19 associated cytokine storm (COVID-CS). Insufficient viral clearance and persistence of a strong cytokine response despite inadequate antiviral immunity seem to be the main mechanisms underlying the pathogenesis. The diagnosis of COVID-19 is based on relatively constant clinical symptoms, clinical findings, laboratory tests, and imaging techniques, while the diagnosis of COVID-CS is a rather dynamic process, based on evolving or newly emerging findings during the clinical course. Management of COVID-19 consists of using antiviral agents to inhibit SARS-CoV-2 replication and treating potential complications including the cytokine storm together with general supportive measures. COVID-CS may be treated using appropriate immunosuppressive and immunomodulatory drugs that reduce the level of inappropriate systemic inflammation, which has the potential to cause organ damage. Currently corticosteroids, IL-6 blockers, or IL-1 blockers are most widely used for treating COVID-CS.</dc:description>
  <dc:identifier>https://aperta.ulakbim.gov.trrecord/227983</dc:identifier>
  <dc:identifier>oai:zenodo.org:227983</dc:identifier>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>http://www.opendefinition.org/licenses/cc-by-sa</dc:rights>
  <dc:source>Turkish Journal of Biology 45(SI-1) 372-389</dc:source>
  <dc:subject>COVID-19</dc:subject>
  <dc:subject>SARS-CoV-2</dc:subject>
  <dc:subject>cytokine storm</dc:subject>
  <dc:subject>acute respiratory distress syndrome</dc:subject>
  <dc:subject>tocilizumab</dc:subject>
  <dc:subject>anakinra</dc:subject>
  <dc:title>Pathogenesis and treatment of cytokine storm in COVID-19</dc:title>
  <dc:type>info:eu-repo/semantics/article</dc:type>
  <dc:type>publication-article</dc:type>
</oai_dc:dc>